Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial

Pertuzumab plus trastuzumab (P+T) in patients (Pts) with colorectal cancer (CRC) with ERBB2 amplification or overexpression: Results from the TAPUR Study.

(2020) Ranju Gupta et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): DESTINY-CRC01.

(2020) Salvatore Siena et al.   JOURNAL OF CLINICAL ONCOLOGY

Central Nervous System as Possible Site of Relapse in ERBB2-Positive Metastatic Colorectal Cancer

(2020) Andrea Sartore-Bianchi et al.   JAMA Oncology

Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study

(2019) Funda Meric-Bernstam et al.   LANCET ONCOLOGY

Plasma HER2 (ERBB2) Copy Number Predicts Response to HER2-targeted Therapy in Metastatic Colorectal Cancer

(2019) Giulia Siravegna et al.   CLINICAL CANCER RESEARCH

Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2–positive advanced breast cancer: Final results from MARIANNE

(2019) Edith A. Perez et al.   CANCER

HER2-targeted therapies — a role beyond breast cancer

(2019) Do-Youn Oh et al.   Nature Reviews Clinical Oncology

HER2 and Breast Cancer — A Phenomenal Success Story

(2019) Daniel F. Hayes   NEW ENGLAND JOURNAL OF MEDICINE

526PDTRIUMPH: Primary efficacy of a phase II trial of trastuzumab (T) and pertuzumab (P) in patients (pts) with metastatic colorectal cancer (mCRC) with HER2 (ERBB2) amplification (amp) in tumour tissue or circulating tumour DNA (ctDNA): A GOZILA sub-study

(2019) Y Nakamura et al.   ANNALS OF ONCOLOGY

527PDTrastuzumab and tucatinib for the treatment of HER2 amplified metastatic colorectal cancer (mCRC): Initial results from the MOUNTAINEER trial

(2019) J H Strickler et al.   ANNALS OF ONCOLOGY

Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q

(2019) K L Jhaveri et al.   ANNALS OF ONCOLOGY

Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer

(2018) S Siena et al.   ANNALS OF ONCOLOGY

Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer

(2018) Giulia Siravegna et al.   CANCER CELL

A multi-histology basket trial of ado-trastuzumab emtansine in patients with HER2 amplified cancers.

(2018) Bob T. Li et al.   JOURNAL OF CLINICAL ONCOLOGY

146TiPA multicenter, multicohort, phase II study of trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing metastatic colorectal cancer

(2018) T Yoshino et al.   ANNALS OF ONCOLOGY

Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2–Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study

(2017) Edith A. Perez et al.   JOURNAL OF CLINICAL ONCOLOGY

DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1

(2016) Y. Ogitani et al.   CLINICAL CANCER RESEARCH

HER2 amplification as a ‘molecular bait’ for trastuzumab-emtansine (T-DM1) precision chemotherapy to overcome anti-HER2 resistance in HER2 positive metastatic colorectal cancer: The HERACLES-RESCUE trial.

(2016) Salvatore Siena et al.   JOURNAL OF CLINICAL ONCOLOGY

Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial

(2016) Andrea Sartore-Bianchi et al.   LANCET ONCOLOGY

Assessment of a HER2 scoring system for colorectal cancer: results from a validation study

(2015) Emanuele Valtorta et al.   MODERN PATHOLOGY

IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapies

(2015) Eugenia R. Zanella et al.   Science Translational Medicine

Phase IIa Trial of Trastuzumab Emtansine With Pertuzumab for Patients With Human Epidermal Growth Factor Receptor 2–Positive, Locally Advanced, or Metastatic Breast Cancer

(2014) Kathy D. Miller et al.   JOURNAL OF CLINICAL ONCOLOGY

New Routes to Targeted Therapy of Intrahepatic Cholangiocarcinomas Revealed by Next-Generation Sequencing

(2014) J. S. Ross et al.   ONCOLOGIST

A Molecularly Annotated Platform of Patient-Derived Xenografts ("Xenopatients") Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal Cancer

(2011) A. Bertotti et al.   Cancer Discovery